Zhu Lina, Li Lanjun, Wu Jun
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, China.
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, China..
Autoimmun Rev. 2025 Feb 28;24(3):103719. doi: 10.1016/j.autrev.2024.103719. Epub 2024 Dec 11.
Pathogenic IgG autoantibodies play a crucial role in the pathogenesis of autoimmune diseases, and removal of pathogenic IgG autoantibodies is an important therapeutic approach and tool for such diseases. The neonatal Fc receptor (FcRn) interacts with IgG and protects it from lysosomal degradation. FcRn inhibitors accelerate the clearance of IgG antibodies, including pathogenic IgG autoantibodies, by targeting and blocking the binding of FcRn to IgG. Theoretically, FcRn inhibitors can be applied for the treatment of IgG-mediated autoimmune diseases. With successful completion of multiple relevant clinical trials, key evidence-based data have been provided for FcRn inhibitors in the treatment of IgG-mediated autoimmune diseases, and several FcRn inhibitors have been approved for these indications. Additional trials are being planned or conducted. This review examines all available high-quality clinical trials of FcRn inhibitors assessing IgG-mediated autoimmune diseases.
致病性IgG自身抗体在自身免疫性疾病的发病机制中起关键作用，清除致病性IgG自身抗体是此类疾病的重要治疗方法和手段。新生儿Fc受体（FcRn）与IgG相互作用并保护其免受溶酶体降解。FcRn抑制剂通过靶向和阻断FcRn与IgG的结合来加速IgG抗体（包括致病性IgG自身抗体）的清除。从理论上讲，FcRn抑制剂可用于治疗IgG介导的自身免疫性疾病。随着多项相关临床试验的成功完成，已为FcRn抑制剂治疗IgG介导的自身免疫性疾病提供了关键的循证数据，并且几种FcRn抑制剂已被批准用于这些适应症。更多试验正在计划或进行中。本综述考察了所有评估FcRn抑制剂治疗IgG介导的自身免疫性疾病的高质量临床试验。
